Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance and Market Dynamics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [1][2]. - The turnover rate of 30.107% indicates a significant shift in shareholding structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [2]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support line for future price movements [2]. Group 2: Market Sentiment and Trading Behavior - The K-line pattern during this period showed a paradox where the stock rose for four days but only recorded three bullish candles, indicating a fierce battle between bulls and bears [3][5]. - Despite the apparent selling pressure, the volume of buying was significantly higher, with bullish volume at 3.572 billion shares, which is 14.88 times the bearish volume, indicating strong buying interest [6]. Group 3: Investor Composition and Market Drivers - Southbound funds were identified as the primary drivers of this rally, with nearly 944.3 million shares acquired through the Stock Connect channels within just five days, representing 0.7458% of the total issued shares [7][9]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [9]. Group 4: Future Outlook - The stock is currently in a high volatility phase following a significant price increase, with ongoing battles between buyers and sellers in the 10.00-11.00 HKD range [10]. - The future price stability will depend on two key factors: the continued inflow of southbound funds and the company's ability to validate its high growth potential to match the new valuation [10].

Group 1 - A total of 161 stocks reached a 52-week high as of September 15, with notable performers including Yaojie Ankang-B (02617) at 71.60%, Chengan Technology (08131) at 60.83%, and Brainstorm Aurora-B (06681) at 45.51% [1] - The highest closing price for Yaojie Ankang-B was 415.000, with a peak of 431.400, indicating strong market interest [1] - Chengan Technology's stock closed at 0.128, reaching a high of 0.193, reflecting significant growth potential [1] Group 2 - Other notable stocks that reached new highs include Baize Medical (02609) with a high rate of 33.61%, and BENG SOON MACH (01987) at 27.66% [1] - The list of stocks achieving new highs also includes Jinsheng Group (00794) at 26.67% and Feiyu Technology (01022) at 21.52% [1] - The data indicates a robust performance across various sectors, suggesting a positive market sentiment [1] Group 3 - The report also highlights stocks that reached new lows, with Minshang Chuangke (01632) experiencing a decline of 34.71% [5] - Other stocks that saw significant drops include XI Ernan Tesla (07366) at -17.65% and XI Ernan Tesla-U (09366) at -17.17% [5] - The presence of declining stocks alongside those reaching new highs indicates a mixed market environment [5]

Group 1 - The Hang Seng Index rose by 0.29%, gaining 75 points to reach 26,463 points, while the Hang Seng Tech Index increased by 1.11%. The early trading volume in Hong Kong was HKD 162 billion [1] - CRO concept stocks saw significant gains, with Kanglong Chemical (03759) rising over 8% due to accelerated clinical trial review and approval processes. Other notable performers included Zhaoyan New Drug (06127) up 7%, WuXi Biologics (02269) up 5.5%, and Kelaiying (06821) up 4.2% [1] Group 2 - Yaojie Ankang (02617) surged over 33% after being included in the Hong Kong Stock Connect list, effective from September 8 [2] - The lithium battery sector performed well, with Morgan Stanley issuing a positive report on CATL, as market attention shifts to lithium demand expectations for next year. Notable stock movements included Zhongxin Hang (03931) up 4%, CATL (03750) up 7%, and Ganfeng Lithium (01772) up 4% [2] Group 3 - Yunfeng Financial (00376) increased by over 19%, with its stock price doubling within the month following the approval of its virtual asset trading services [3] Group 4 - Ruipu Lanjun (00666) rose nearly 2%, driven by sustained high production levels at major battery manufacturers and a significant increase in the company's energy storage battery shipments [4] Group 5 - Hushang Ayi (02589) gained over 8% after being included in the Hong Kong Stock Connect list, with stable growth in store numbers during the first half of the year [5] - Brainstorm Cell Therapeutics-B (06681) saw a dramatic rise, initially up 83% to a record high, and closing up 36%, with a cumulative increase of over 130% since its inclusion in the Stock Connect list on September 8. The company is noted for developing the first medical-grade digital therapy product for cognitive disorders in China [5] Group 6 - Baiao Saitu-B (02315) increased by over 11% after signing an antibody selection rights evaluation agreement with Merck to advance antibody-drug conjugate lipid delivery solutions [6] Group 7 - Domestic property stocks collectively declined, with Shimao Group (00813) falling nearly 5% and Zhongliang Holdings (02772) dropping over 3% [7]

Group 1 - The market perceives that companies listed on the Hong Kong stock market benefit from being included in the Hong Kong Stock Connect, as it attracts southbound capital and enhances company visibility [1] - Brain动极光-B (06681.HK) experienced a significant price increase, rising by 32% last Friday and peaking at over 80% before a notable pullback, ultimately trading at HKD 10.4, reflecting a nearly 40% increase [1] - Since entering the Hong Kong Stock Connect, Brain动极光-B has seen its stock price nearly double, with a peak increase exceeding 100% within a week [1] Group 2 - Brain动极光 is the first Chinese company to combine brain science with advanced artificial intelligence to develop medical-grade digital therapy products for cognitive impairments [3] - The company's product pipeline addresses a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children [3] - In the first half of this year, Brain动极光 reported revenue of RMB 100 million, marking a year-on-year growth of 92.82% [3] Group 3 - Other stocks that entered the Hong Kong Stock Connect on September 8 also experienced significant price increases, such as药捷安康-B (02617.HK) with a cumulative rise of over 220% and映恩生物-B (09606.HK) with a cumulative rise of over 30% [3]

格隆汇9月15日｜港股市场脑机接口概念股脑动极光-B(6681.HK)拉升大涨超80%，报13.78港元，为连续 第三日上涨，股价创上市新高，截至目前成交额放大至7亿港元。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

格隆汇9月15日｜港股市场脑机接口概念股脑动极光-B(6681.HK)拉升大涨超80%，报13.78港元，为连续 第三日上涨，股价创上市新高，截至目前成交额放大至7亿港元。 ...

Core Viewpoint - Brainstorming Aurora-B (06681) experienced a significant stock price increase, reaching a new high since its listing, following its inclusion in the Hong Kong Stock Connect program [1] Group 1: Stock Performance - The stock surged over 83% in early trading, peaking at 13.78 HKD, marking a cumulative increase of 1.3 times since its market entry [1] - As of the report, the stock was up 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] Group 2: Company Developments - Starting from September 8, Brainstorming Aurora was officially included in the Hong Kong Stock Connect list [1] - The company is recognized as the first in China to develop medical-grade digital therapy products targeting cognitive disorders, with its core product being the first to receive regulatory approval in this category (registered in September 2018) [1] - On September 12, the company announced via its official WeChat account that its series of products received the Beijing New Technology, New Product, and New Service Certificate [1] Group 3: Product Features - The products focus on intelligent assessment and precise intervention, boasting several advantages: reliance on large sample norms for accurate evaluation, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

Core Viewpoint - Brain动极光-B (06681) has seen a significant stock price increase, rising over 83% to a new high of 13.78 HKD since its listing, with a cumulative increase of 1.3 times since its debut [1] Group 1: Stock Performance - As of the latest update, the stock price has increased by 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] - The stock was officially included in the Hong Kong Stock Connect list starting September 8 [1] Group 2: Company Overview - Brain动极光 is the first domestic company to develop medical-grade digital therapy products targeting cognitive disorders [1] - Its core product is the first cognitive disorder digital therapy product in China to receive regulatory approval, obtaining its first registration certificate in September 2018 [1] Group 3: Product Features - The company's products have recently received the Beijing New Technology, New Product, and New Service Certificate [1] - The products focus on intelligent assessment and precise intervention, featuring advantages such as precise evaluation based on large sample norms, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

9月12日，脑动极光(06681.HK)涨超50%，高见9.47港元创上市新高。截至发稿，涨50.44%，报8.52港 元，成交额5.79亿港元。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Brainstorm Aurora (06681), which rose over 50% to reach a new high of 9.47 HKD following its inclusion in the Hong Kong Stock Connect program effective September 8, 2025 [1] - As of the report, the stock was trading at 8.52 HKD with a trading volume of 579 million HKD, reflecting strong market interest [1] - The company reported a revenue of 100 million HKD for the first half of 2025, representing a year-on-year increase of 92.82% [1] Group 2 - The company has made significant advancements in its core pipeline in research and clinical trials, achieving commercialization for eight indications across four major types of cognitive disorders [1] - Additionally, the company is actively developing treatments for other cognitive disorder indications [1] - The company is pushing for innovation and application of AI in the medical field, having developed a proprietary medical large model, BrainAuGPT, which received a national invention patent for its novel training task combination method based on GBR second-order knowledge representation [1]